 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «1234567891011» |
- Resolute ZES (zotarolimus-eluting stent) / Medtronic
[VIRTUAL] FINAL TWO-YEAR RESULTS FROM THE RANDOMIZED ONYX ONE TRIAL IN HIGH BLEEDING RISK PATIENTS TREATED WITH 1-MONTH DAPT (Topic Essentials 1) - Feb 17, 2021 - Abstract #ACC2021ACC_41;
Patients received DAPT for 1 month after the procedure and single antiplatelet therapy (SAPT) thereafter (aspirin or clopidogrel at operator choice). Two-year results from Onyx ONE RCT demonstrate non-significant differences for the primary and powered secondary outcomes after PCI with Resolute Onyx DES compared with BioFreedom DCS in HBR patients treated with SAPT after 1-month DAPT.
- || sirolimus / Generic mfg.
Clinical, Journal: Treating diabetic all-comers with contemporary drug-eluting stents: Prespecified comparisons from the BIO-RESORT and the BIONYX randomized trials. (Pubmed Central) - Feb 12, 2021
In addition there was no difference in clinical outcome in diabetic patients, who were treated with SES versus RO-ZES. These findings may be considered as a signal of safety and efficacy of the studied DES in patients with diabetes.
- | sirolimus / Generic mfg.
Clinical, Clinical data, Journal: Clinical outcomes of contemporary drug-eluting stents in patients with and without diabetes mellitus: Multigroup propensity-score analysis using data from stent-specific, multicenter, prospective registries. (Pubmed Central) - Feb 3, 2021
These findings may be considered as a signal of safety and efficacy of the studied DES in patients with diabetes. In this clinical-practice registry study, regardless the diabetic status, the 3-year rates of the primary outcome were similar among different types of DES, suggesting no differential clinical response between contemporary DES in patients with or without diabetes.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Journal: Two-year follow-up of a randomized multicenter study comparing a drug-coated balloon with a drug-eluting stent in native small coronary vessels: The RESTORE Small Vessel Disease China trial. (Pubmed Central) - Feb 3, 2021
Compared to the second-generation DES, the RESTORE DCB did not increase the risk of clinical outcomes. Late catch-up phenomen requiring revascularization was not significant in this study.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial completion date: Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion (BIO-RESORT) (clinicaltrials.gov) - Jan 27, 2021
P=N/A, N=3514, Active, not recruiting, Sponsor: Foundation of Cardiovascular Research and Education Enschede
Late catch-up phenomen requiring revascularization was not significant in this study. Trial completion date: Aug 2020 --> Aug 2021
- ||| Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial completion, Trial completion date: The IRIS-Resolute Integrity (IRIS-Integrity) (clinicaltrials.gov) - Jan 27, 2021
P=N/A, N=3000, Completed, Sponsor: Seung-Jung Park
Trial completion date: Aug 2020 --> Aug 2021 Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Mar 2020
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
If available Megatron. Otherwise I would choose the ones which have 3 rather than 2 connectors and bit thicker struts. Also some suggest slotted tube stents (lasered) eg Resolute Onyx have more rad strength than coiled stents. But there are certainly better experts to comment. (Twitter) - Jan 26, 2021
- || sirolimus / Generic mfg.
Clinical, Journal: Comparison of First- and Second-Generation Drug-Eluting Stents in Patients with ST-Segment Elevation Myocardial Infarction Based on Pre-Percutaneous Coronary Intervention Thrombolysis in Myocardial Infarction Flow Grade. (Pubmed Central) - Jan 23, 2021
In this study, 2G-DES showed better clinical outcomes than 1G-DES concerning MACEs and any repeat revascularization regardless of pre-TIMI. However, more research is needed to support these results.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Enrollment closed, Trial completion date, Trial primary completion date: SUGAR: Second-generation Drug-eluting Stents in Diabetes (clinicaltrials.gov) - Jan 19, 2021
P4, N=1164, Active, not recruiting, Sponsor: Spanish Society of Cardiology
However, more research is needed to support these results. Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Jan 2022 | Trial primary completion date: Oct 2020 --> Jan 2021
- || sirolimus / Generic mfg.
Clinical, Journal: 10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents. (Pubmed Central) - Jan 13, 2021
P4
High overall adverse clinical event rates were observed during extended follow-up. (Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus-Eluting Stents [ISAR-TEST-5]; NCT00598533).
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Clinical data, Journal: Comparison of 3-year clinical outcomes between Endeavor Resolute® and Resolute Integrity® zotarolimus-eluting stents in an Asian population. (Pubmed Central) - Jan 13, 2021
However, these results can perhaps be more precisely defined by other large and long-term follow-up studies in the future. (Anatol J Cardiol 2020; 23: 268-76).
- ||| Resolute ZES (zotarolimus-eluting stent) / Medtronic
Enrollment open: The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries (clinicaltrials.gov) - Dec 23, 2020
P=N/A, N=444, Recruiting, Sponsor: Elixir Medical Corporation
(Anatol J Cardiol 2020; 23: 268-76). Not yet recruiting --> Recruiting
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Journal: Long-term (5-year) clinical evaluation of the Resolute zotarolimus-eluting coronary stent: The RESOLUTE US clinical trial. (Pubmed Central) - Dec 19, 2020
Not yet recruiting --> Recruiting Results from the fully adjudicated and monitored RESOLUTE US trial demonstrate long-term 5-year safety and efficacy of the R-ZES stent among a relatively low-risk population of patients, including a 0.5% rate of stent thrombosis at 5 years.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Clinical data, Journal: BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: three-year clinical outcomes of the PIONEER trial. (Pubmed Central) - Dec 18, 2020
Results from the fully adjudicated and monitored RESOLUTE US trial demonstrate long-term 5-year safety and efficacy of the R-ZES stent among a relatively low-risk population of patients, including a 0.5% rate of stent thrombosis at 5 years. No abstract available
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Journal: Efficacy of Zotarolimus-Eluting Stents in Treating Diabetic Coronary Lesions: An Optical Coherence Tomography Study. (Pubmed Central) - Dec 17, 2020
P=N/A
Although more neointimal proliferation and more neovascularization were found in diabetic coronary lesions when compared with non-diabetic lesions, treatment with ZES showed similar stent malapposition rate at 1-year follow-up. The data indicated that ZES treatment could possibly be effective in treating diabetic coronary lesions.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Journal: Panta rhei, also drug eluting stent technology. (Pubmed Central) - Dec 16, 2020
This prospective, multicenter, single arm study, showed favorable 5-year outcomes in patients undergoing Resolute ZES implantation, with considerably low rate of repeated revascularization and stent thrombosis. Data on long-term performance of next-generation drug eluting stents are of paramount importance to adequately inform decision-making in contemporary clinical practice.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Enrollment open, Trial completion date, Trial primary completion date: The Rolex Registry (Revascularization Of LEft Main With Resolute onyX) (clinicaltrials.gov) - Dec 3, 2020
P=N/A, N=450, Recruiting, Sponsor: University of Padova
Data on long-term performance of next-generation drug eluting stents are of paramount importance to adequately inform decision-making in contemporary clinical practice. Not yet recruiting --> Recruiting | Trial completion date: Dec 2020 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Dec 2021
- ||| Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial completion, Trial completion date: Onyx ONE: A Randomized Controlled Trial With Resolute Onyx in One Month Dual Antiplatelet Therapy (DAPT) for High-Bleeding Risk Patients (clinicaltrials.gov) - Dec 2, 2020
P=N/A, N=2000, Completed, Sponsor: Medtronic Vascular
Not yet recruiting --> Recruiting | Trial completion date: Dec 2020 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Dec 2021 Active, not recruiting --> Completed | Trial completion date: Aug 2021 --> Oct 2020
- ||| Resolute ZES (zotarolimus-eluting stent) / Medtronic
Enrollment open: Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT) (clinicaltrials.gov) - Nov 23, 2020
P=N/A, N=2400, Recruiting, Sponsor: Elixir Medical Corporation
Active, not recruiting --> Completed | Trial completion date: Aug 2021 --> Oct 2020 Not yet recruiting --> Recruiting
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Journal: Thin Composite-Wire-Strut Zotarolimus-Eluting Stents Versus Ultrathin-Strut Sirolimus-Eluting Stents in BIONYX at 2 Years. (Pubmed Central) - Nov 14, 2020
P=N/A
At 2-year follow-up, the novel thin composite-wire-strut durable-polymer Resolute Onyx ZES showed in all-comers similar safety and efficacy compared with the ultrathin cobalt-chromium-strut biodegradable-polymer Orsiro SES. The analysis of patients who were treated in small vessels also suggested no advantage for either stent.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Journal: Randomized Comparison of Everolimus- and Zotarolimus-Eluting Coronary Stents With Biolimus-Eluting Stents in All-Comer Patients. (Pubmed Central) - Nov 12, 2020
P=N/A, P2
However, caution is advised regarding interpretation of these results due to the premature termination of this study. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01397175.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Journal: Initial Experience With the Next-Generation Resolute Onyx Zotarolimus-Eluting Stent in Symptomatic Intracranial Atherosclerotic Disease. (Pubmed Central) - Oct 28, 2020
The use of R-onyx DES in the treatment of sICAD is safe with high technical success rates. Large prospective multicenter trials with long-term follow-up are warranted.
- | sirolimus / Generic mfg.
Journal: Device Comparisons in the New-Generation Drug-Eluting Stent Era: Continued Refinements in Stent Technology. (Pubmed Central) - Oct 27, 2020
Large prospective multicenter trials with long-term follow-up are warranted. No abstract available
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Journal: Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI): A prespecified prospective register from the DAPT-STEMI trial. (Pubmed Central) - Oct 25, 2020
P4
The present analysis is the largest to date reporting short-term and mid-term clinical outcomes with the R-ZES stent in setting of STEMI. At 30 days and 6-months R-ZES has an outstanding safety and efficacy even in this high-risk category of patients.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial primary completion date: RESOLUTE ONYX China Single Arm Study (clinicaltrials.gov) - Oct 22, 2020
P=N/A, N=591, Active, not recruiting, Sponsor: Medtronic Vascular
At 30 days and 6-months R-ZES has an outstanding safety and efficacy even in this high-risk category of patients. Trial primary completion date: Sep 2020 --> Mar 2021
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial primary completion date: RESOLUTE ONYX China RCT Study (clinicaltrials.gov) - Oct 22, 2020
P=N/A, N=550, Active, not recruiting, Sponsor: Medtronic Vascular
Trial primary completion date: Sep 2020 --> Mar 2021 Trial primary completion date: Sep 2020 --> Mar 2021
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Journal: Comparison of one year outcomes between the ihtDEStiny stent and the durable polymer everolimus and zotarolimus eluting stents. A propensity score matched analysis. (Pubmed Central) - Oct 20, 2020
The use of ihtDEStiny stent in real practice is associated with a clinical performance at 12 months follow up that appears to be non-inferior to the most widely used and largely evidence supported durable polymer drug eluting stents. A longer follow up is warranted.
- |||| Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial completion, Enrollment change: Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside) (clinicaltrials.gov) - Oct 20, 2020
P4, N=219, Completed, Sponsor: Scripps Health
A longer follow up is warranted. Active, not recruiting --> Completed | N=900 --> 219
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Enrollment open, HEOR: IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact (clinicaltrials.gov) - Oct 19, 2020
P=N/A, N=3100, Recruiting, Sponsor: Medstar Health Research Institute
Active, not recruiting --> Completed | N=900 --> 219 Not yet recruiting --> Recruiting
- || Taltorvic (ridaforolimus) / Takeda, Merck (MSD), Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Clinical data, Journal: Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 2-Year Clinical Outcomes From the BIONICS and NIREUS Trials. (Pubmed Central) - Oct 7, 2020
In a pooled analysis of 2 randomized trials, 2-year clinical outcomes were similar between patients undergoing percutaneous coronary intervention with RES and ZES. These results support the long-term safety and efficacy of RES for the treatment of a broad population of patients with coronary artery disease.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
Journal: Propensity score-matched analysis of coronary artery bypass grafting versus second-generation drug-eluting stents for triple-vessel disease. (Pubmed Central) - Oct 2, 2020
These results support the long-term safety and efficacy of RES for the treatment of a broad population of patients with coronary artery disease. CABG might be superior to PCI with second-generation DESs for treatment of triple-vessel disease in terms of major adverse cardiac and cerebrovascular events.
- |||| Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical: “The DES (Resolute Onyx) is the first and only stent in the U.S. that is safe and effective in HBR patients with one-month DAPT, according to a press release from the company.” @Medtronic @US_FDA @ajaykirtane #CardioTwitter https://t.co/RzZbB0Pzii (Twitter) - Oct 2, 2020
- |||| Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical: ICYMI: The DES (Resolute Onyx) is the first and only stent in the U.S. that is safe and effective in this particular patient population @Medtronic @US_FDA @ajaykirtane #CardioTwitter https://t.co/RzZbB0Pzii (Twitter) - Oct 1, 2020
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
Clinical, Journal, Real-World Evidence: Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry. (Pubmed Central) - Sep 30, 2020
In the propensity score-matched cohort, the stent-related outcome (EES vs. BES vs. ZES; 5.9% vs. 6.7% vs. 7.1%, P = 0.226) and patient-related outcomes (12.7% vs. 13.5% vs. 14.3%, P = 0.226) and patient-related outcomes (12.7% vs. 13.5% vs. 14.3%, P = 0.226) and patient-related outcomes (12.7% vs. 13.5% vs. 14.3%, P = 0.226) and patient-related outcomes (12.7% vs. 13.5% vs. 14.3%. In this robust real-world registry with unrestricted use of EES, BES, and ZES, the three stent groups showed comparable safety and efficacy at the 3-year follow-up.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
Trial completion date, Trial primary completion date: SHEAR-STENT: Wall Shear Stress and Neointimal Healing Following PCI in Angulated Coronary Vessels (clinicaltrials.gov) - Sep 25, 2020
P=N/A, N=126, Recruiting, Sponsor: Emory University
In this robust real-world registry with unrestricted use of EES, BES, and ZES, the three stent groups showed comparable safety and efficacy at the 3-year follow-up. Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Jun 2020 --> Dec 2020
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
New trial: TARGET-IV_NA: Firehawk Rapamycin Target Eluting Coronary Stent North American Trial (clinicaltrials.gov) - Sep 23, 2020
P, N=0, Withheld, Sponsor: [Redacted]
- ||| Resolute ZES (zotarolimus-eluting stent) / Medtronic
New trial: Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT) (clinicaltrials.gov) - Sep 23, 2020
P=N/A, N=2400, Not yet recruiting, Sponsor: Elixir Medical Corporation
- || Taltorvic (ridaforolimus) / Takeda, Merck (MSD), Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Journal: Percutaneous Coronary Intervention Does Not Lower Cardiovascular Outcomes in Patients with Chronic Kidney Disease. (Pubmed Central) - Sep 23, 2020
Moderate-CKD in patients with CAD was associated with higher rates of all-cause and cardiovascular mortality, yet with a lower risk of revascularization 1-year following PCI. Lack of guideline-directed medical therapy does not explain the adverse outcome of CKD patients.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial initiation date: The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries (clinicaltrials.gov) - Sep 15, 2020
P=N/A, N=474, Not yet recruiting, Sponsor: Elixir Medical Corporation
Lack of guideline-directed medical therapy does not explain the adverse outcome of CKD patients. Initiation date: Jul 2020 --> Nov 2020
- | sirolimus / Generic mfg.
Journal: Thin, Very Thin, or Ultrathin Strut Biodegradable- or Durable-Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT. (Pubmed Central) - Sep 8, 2020
P=N/A
Despite substantial differences in stent backbone and polymer coating, all 3 DES showed favorable 3-year safety and efficacy in all comers, without significant between-stent differences. Further follow-up is required to definitely answer the question of whether one stent might improve clinical outcomes at a later stage.
- || Taltorvic (ridaforolimus) / Takeda, Merck (MSD), Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Journal: Outcomes of Patients With Coronary Arterial Bifurcation Narrowings Undergoing Provisional 1-Stent Treatment (from the BIONICS Trial). (Pubmed Central) - Sep 1, 2020
In conclusion, patients with bifurcation lesions treated and a provisional strategy experienced similar outcomes as those with nonbifurcation lesions. RES performed as well as ZES in bifurcation and nonbifurcation lesions.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial completion date, Trial initiation date, Trial primary completion date, HEOR: IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact (clinicaltrials.gov) - Aug 13, 2020
P=N/A, N=3100, Not yet recruiting, Sponsor: Megan Rowland
RES performed as well as ZES in bifurcation and nonbifurcation lesions. Trial completion date: Dec 2024 --> Aug 2025 | Initiation date: Feb 2020 --> Sep 2020 | Trial primary completion date: Sep 2024 --> Apr 2024
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
Clinical, Journal: Comparison of Durable-Polymer- and Biodegradable-Polymer-Based Newer-Generation Drug-Eluting Stents in Patients with Acute Myocardial Infarction and Prediabetes After Successful Percutaneous Coronary Intervention. (Pubmed Central) - Aug 13, 2020
The cumulative incidence of ST was also comparable between the DP-DES and BP-DES groups (aHR: 1.407; 95% CI, 0.476-4.158; P = 0.537). Moreover, the 2-year aHRs of all-cause death, CD, re-MI, target lesion revascularization (TLR), target vessel revascularization (TVR), and non-TVR were similar.Patients with AMI and prediabetes who received DP-DES or BP-DES during PCI showed comparable safety and efficacy during the 2-year follow-up period.
- ||||| Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial completion: First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme and Resolute Integrity in Patients With de Novo Coronary Artery Stenosis (clinicaltrials.gov) - Aug 9, 2020
P2/3, N=168, Completed, Sponsor: Sino Medical Sciences Technology Inc.
Moreover, the 2-year aHRs of all-cause death, CD, re-MI, target lesion revascularization (TLR), target vessel revascularization (TVR), and non-TVR were similar.Patients with AMI and prediabetes who received DP-DES or BP-DES during PCI showed comparable safety and efficacy during the 2-year follow-up period. Active, not recruiting --> Completed
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
Clinical, Journal: Long-Term Comparison of Platinum Chromium Everolimus-Eluting Stent vs. Cobalt Chromium Zotarolimus-Eluting Stent - 3-Year Outcomes From the HOST-ASSURE Randomized Clinical Trial. (Pubmed Central) - Aug 2, 2020
Active, not recruiting --> Completed PtCr-EES and CoCr-ZES had similar and excellent long-term outcomes in both efficacy and safety after PCI in an all-comer population.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
Clinical, Clinical data, Journal: Comparison of short-term clinical outcomes between Resolute Onyx zotarolimus-eluting stents and everolimus-eluting stent in patients with acute myocardial infarction: Results from the Korea Acute Myocardial infarction Registry (KAMIR). (Pubmed Central) - Jul 31, 2020
PtCr-EES and CoCr-ZES had similar and excellent long-term outcomes in both efficacy and safety after PCI in an all-comer population. The present study shows that implantation of O-ZES or EES provided similar clinical outcomes with similar risk at 6-month of TLF and definite/probable ST in patients with AMI undergoing successful PCI.
- Resolute ZES (zotarolimus-eluting stent) / Medtronic
[VIRTUAL] Diabetic patients treated with novel thin composite-wire strut zotarolimus-eluting stents versus ultrathin strut sirolimus-eluting stents in the BIONYX trial: 2-year results of a prespecified analysis () - Jul 30, 2020 - Abstract #ESC2020ESC_3223;
P=N/A
The present study shows that implantation of O-ZES or EES provided similar clinical outcomes with similar risk at 6-month of TLF and definite/probable ST in patients with AMI undergoing successful PCI. In patients with diabetes, the novel thin composite-wire strut durable polymer ZES was similarly safe and efficacious as compared to the ultrathin cobalt-chromium strut biodegradable-polymer SES at 2-year follow-up.
- Resolute ZES (zotarolimus-eluting stent) / Medtronic
[VIRTUAL] Comparison of two iterations of the zotarolimus-eluting stents: an analysis of all-comer patients from two consecutive randomised clinical trials () - Jul 30, 2020 - Abstract #ESC2020ESC_3199;
The novel ZES showed similar 2-year clinical outcomes as compared to its predecessor. Furthermore, there was a positive safety signal regarding the incidence of target vessel myocardial infarction and a particularly low stent thrombosis rates with the novel ZES.
- Resolute ZES (zotarolimus-eluting stent) / Medtronic
[VIRTUAL] Onyx ONE: Outcomes in patients with acute coronary syndrome () - Jul 30, 2020 - Abstract #ESC2020ESC_567;
In Onyx ONE, high-bleeding risk patients presenting with ACS had similar safety and efficacy at 1 year in both the ZES and DCS stent groups. However, a trend was present for greater safety with the ZES with SAPT treatment beyond 30 days driven by lower myocardial infarction rates in that time period thus warranting additional confirmatory studies.
- || sirolimus / Generic mfg.
Clinical, Journal, HEOR: Comparative effectiveness of different contemporary drug-eluting stents in routine clinical practice: a multigroup propensity score analysis using data from the stent-specific, multicenter, prospective registries. (Pubmed Central) - Jul 29, 2020
However, a trend was present for greater safety with the ZES with SAPT treatment beyond 30 days driven by lower myocardial infarction rates in that time period thus warranting additional confirmatory studies. In this comparative effectiveness research using stent-specific, clinical practice registries involving unrestricted use of several contemporary DES, there were no significant between-group differences in the 3-year rates of target-vessel failure.